STOCK TITAN

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Viracta Therapeutics, a clinical-stage precision oncology company, is set to present at the RBC Capital Markets Global Healthcare Conference. The event will feature the President and CEO, Mark Rothera, and the Chief Medical Officer, Dr. Darrel P. Cohen. The presentation is scheduled for May 14, 2024, at 11:00 a.m. EDT and will be available for live webcast and archived on the Viracta website.

Positive
  • None.
Negative
  • None.

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, President and Chief Executive Officer, and Darrel P. Cohen, M.D., Ph.D., Chief Medical Officer, are scheduled to participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 11:00 a.m. EDT.

A live webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Webcasts" and archived for 90 days.

About Viracta Therapeutics, Inc.
Viracta is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV+ nasopharyngeal carcinoma (NPC) and other advanced EBV+ solid tumors. Viracta is also pursuing the application of its “Kick and Kill” approach in other EBV-related diseases.

For additional information, please visit www.viracta.com.

Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communications
Viracta Therapeutics, Inc.
abarreto@viracta.com

SOURCE Viracta Therapeutics, Inc.


FAQ

When is Viracta Therapeutics scheduled to present at the RBC Capital Markets Global Healthcare Conference?

Viracta Therapeutics is set to present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 11:00 a.m. EDT.

Who will be participating in the fireside chat at the conference?

Mark Rothera, President and CEO, and Darrel P. Cohen, M.D., Ph.D., Chief Medical Officer, are scheduled to participate in the fireside chat at the RBC Capital Markets Global Healthcare Conference.

Where can the live webcast of the presentation be accessed?

The live webcast of the presentation will be available on the Investors section of the Viracta website under 'Events and Webcasts'.

How long will the presentation be archived?

The presentation will be archived for 90 days on the Viracta website.

What is the stock symbol of Viracta Therapeutics?

The stock symbol of Viracta Therapeutics is VIRX.

Viracta Therapeutics, Inc.

NASDAQ:VIRX

VIRX Rankings

VIRX Latest News

VIRX Stock Data

9.94M
38.65M
2.84%
50.06%
6.83%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CARDIFF